Macro drivers include surging demand for personalized therapy, government incentives for organ-on-chip toxicology, and the shift from glass/polymer to PDMS for cost-efficient rapid iterations. Key forces reshaping competitive dynamics are: (1) soft-lithography to 3D-printed PDMS technology shifts that compress prototype cycles from weeks to hours; (2) stringent IVDR/FDA guidance pushing manufacturers toward bonded covalent coatings that mitigate drug-absorption variability; and (3) post-pandemic supply-chain re-mapping, driving regional foundry partnerships. North America retains ~42% share, buoyed by NIH translational grants, while Asia-Pacific emerges as the fastest-expanding region at >14% CAGR, fueled by biotech clusters in China, Korea, and Singapore importing high-spec PDMS foundry services.